Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the treatment of moderate-to-severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo-controlled, Phase 2 study
EXPERIMENTAL DERMATOLOGY（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined